Hallway Conversation: Ezogabine

Published Online: Tuesday, March 20, 2012
Follow Pharmacy_Times:
In this podcast, part of Epilepsy.com’s Hallway Conversations series, Joseph Sirven, MD, professor of neurology at Mayo Clinic Arizona and editor-in-chief of Epilepsy.com, interviews Bassel Abou-Khalil, MD, professor of neurology and director of the epilepsy division at Vanderbilt University, about the promising new antiepileptic drug (AED) ezogabine (Potiga), which was approved by the FDA in June 2011.
 
Dr. Abou-Khalil explains that ezogabine, whose generic name is retigabine outside the United States, has a unique mechanism of action for an AED in that it prolongs the opening of the potassium channel. He adds that in clinical trials, some of which he helped run, the drug was very effective at reducing seizure frequency when added to other AEDs. In addition to dizziness, fatigue, and somnolence, which are generally common side effects of AEDs, Dr. Abou-Kahlil notes that urinary retention and discoloration of the urine have been associated with ezogabine.
 
To listen to the podcast, click here and scroll down to the October 14, 2011, episode.
Related Articles
Nearly one in 5 adults with epilepsy show symptoms of attentiondeficit/ hyperactivity disorder (ADHD), according to a recent study.
Epilepsy has scores of factors, each leading to different treatment strategies and complicating the development of an evidence-based approach to seizure control.
According to recent research published on behalf of the International League Against Epilepsy, most patients and caregivers want to be educated about sudden unexpected death in epilepsy.
According to new research, stomach sleepers with epilepsy may be at higher risk of sudden unexpected death in epilepsy.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$